| Biomarker ID | 767 |
| PMID | 21963599 |
| Year | 2012 |
| Biomarker | OPNa (osteopontin -a ) |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated with high Gleason Score (Median for GS< 7: 0.35, Median for GS ≥ 7: 84.54) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Alpha-V beta-3 integrin/OPN pathway,TWEAK regulation of gene expression,Osteopontin signaling,Osteoclast signaling,Beta-3 integrin cell surface interactions |
| Experiment | Gleason Score <7 Vs Gleason Score ≥ 7 |
| Type of Biomarker | Prognostic |
| Cohort | 40 patients with PCA such as 15 have GS <7 and 25 has GS ≥ 7 |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p= 0.006 |
| Method Used | Quantitative real time PCR (qRT-PCR) |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | SPP1 |